VYNE Therapeutics
VYNE
33 hedge funds and large institutions have $18.4M invested in VYNE Therapeutics in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
1,095% more capital invested
Capital invested by funds: $1.54M → $18.4M (+$16.9M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
57% more funds holding
Funds holding: 21 → 33 (+12)
44.91% more ownership
Funds ownership: 11.69% → 56.61% (+45%)
Top Buyers
Top Sellers
VYNE Hedge Fund Activity: Q4 2023 in Review
33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2023, worth a combined $18.4M — up 1,095% from $1.54M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VYNE positions and 1 closed out — a net gain of 12 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $4.35M. The largest seller was Susquehanna International Group, cutting an estimated $48.1K.
- 33 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2023, up from 21 in Q3 2023.
- Funds reported $18.4M of VYNE Therapeutics stock for Q4 2023, up 1,095% quarter-over-quarter.
- 13 funds opened new VYNE Therapeutics positions in Q4 2023 and 1 closed out, a net change of +12 holders.
- The largest VYNE Therapeutics buyer in Q4 2023 was Cormorant Asset Management, an estimated $4.35M added.
- The largest VYNE Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $48.1K sold.
Based on aggregated 13F filings for Q4 2023.